LabCorp Holdings Pricing Spineometer: 5 of 5 Vertebrae

LabCorp, a laboratory services company for medical providers, pharmaceuticals, and researchers, had a positive FY 2024. Revenue rose 7% to $13.0 billion, and operating income rose 50% to $1.1 billion over last year.

A review of Labcorp’s 4 February 2025 earnings call and associated financial reports provided insight regarding the importance of pricing on performance.

FACTS FROM EARNINGS CALL AND ANNUAL REPORT

LabCorp has two operating divisions. Diagnostic Laboratories and Biopharma Laboratory Services.

Diagnostic Laboratories (Dx), which delivers 78% of revenue, is largely a North American business. It has “payers” of clients, patients, Medicare/Medicaid, and third-party insurers. Competitors include hospital-based laboratories, physician office laboratories, and independent laboratories like Labcorp. Most prices for their offerings are set according to a fee schedule determined by government contracts and insurers. As such, price management in this line of business would be a highly administrative role to ensure compliance. Opportunities to apply value-based pricing would largely be restricted to new product development, of which LabCorp launched nearly 100 new tests in 2024.

Biopharma Laboratory Services (BLS), which delivers 22% of revenue, is a globally distributed business. Its clients include pharmaceutical, biotechnology, medical device, and diagnostic companies. Competitors include hundreds of small providers and a limited number of large companies with global capabilities like LabCorp. In this line of business, value-based pricing would be required across the Value-Based Pricing Framework.

Julia Wang, CFO of LabCorp, reported an improvement in revenue attributed to improvements both in volume and price-mix. This relies on a form of variance analysis from managerial accounting.

VALUE-BASED PRICING FRAMEWORK IMPLIED PRICING REQUIREMENTS

Of the 70,000 employees at LabCorp, industry benchmarks would suggest 26 to 130 professionals would manage pricing decisions daily. Based on the complexity of their business, we would recommend the pricing team towards the lower end of this industry benchmark, in the range of 26 to 52.

1. LabCorp spent $839 on acquisitions, or 6% of revenue. Acquiring new offerings is an opportunity to review pricing and commercial policy.
2. BLS operates in over 100 countries. Each country has different commercial practices and presents a different competitive environment. Best practices would suggest collocating pricing expertise in significant regions and markets to manage the variation in industry dynamics.
3. BLS’s salesforce is commission-based and likely negotiates prices with customers. Price variance management and other forms of AI applied to pricing to provide price guardrails to commercial officers would support greater price discipline.
4. With the very wide variety of tests and offerings of LabCorp, price administration and price changes would require a dedicated team.
5. Other issues to consider regarding price management at LabCorp are somewhat supportive of limited pricing capability requirements.

OBSERVED PRICING CAPABILITY

Research into the investment by LabCorp in pricing yielded encouraging results.

1. The pricing team size appears to be above the lower end of industry standards, as expected.
2. Team roles included analysts, managers, directors, and senior directors.
3. Responsibilities included contract management and pricing strategy in different business areas.
4. Pricing experts are located in the United States. None were identified globally, though they may exist.

Given the importance and capability of pricing at LabCorp as indicated in financial reports, management statements, and our pricing team research, and given their performance, we have come to the following conclusion as of September 2025.

LabCorp Pricing Spineometer: 5 out of 5 Vertebrae. From publicly available information, no significant gaps in pricing have been identified. They are expected to exist, but it would require an in-depth consultation to be identified.

LH (LabCorp Holdings, Inc.) rose from 227 the day prior to their earnings call to 230 one week later. FY 2024 revenue of $13 billion with an 8.4% operating margin and a P/E ratio near 16.

For FY 2024, a 1% improvement in price for the BLS division would yield 6% improvement in operating profits for that division, holding all else constant at Labcorp’s BLS division.